BioSpace News Archive

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a call to discuss the recent conclusions of its PURE EP(tm) 2.0 study

Tevogen Bio, a clinical stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TVGN-489, Allogeneic COVID-19 Specific Cytotoxic T Lymphocytes (CTLs), allowing Tevogen Bio to initiate clinical trial of its investigational COVID-19 treatment.

Servier, a global independent pharmaceutical Group, and Nymirum, a pioneer in RNA-targeted small molecules, announced today that they have entered into a strategic collaboration to identify and develop RNA-modulatory drugs for the treatment of neurological diseases.

NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage pharmaceutical company announced today that it has signed a Memorandum Of Understanding with the Government of Israel to license exclusive worldwide development, manufacturing, and marketing rights to a novel Coronavirus vaccine developed by the Israel Institute for Biological Research (IIBR).

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced preliminary results for the second quarter of 2021 that exceeded the outlook for net sales and adjusted earnings per share.

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today has released preliminary Q2 2021 results and an updated outlook for full-year 2021.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the following upcoming investor conferences in July:

Celldex Therapeutics, Inc. announced that it is proposing to offer and sell, subject to market conditions, $175 million of shares of its common stock in an underwritten public offering.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, reported preliminary unaudited results for the second quarter of 2021.

Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2021 after market close on Monday, August 9, 2021 at 4:30 PM Eastern Time